Pharmaceutical Investing Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil
Pharmaceutical Investing Acerus Provides Update on Continuing Commercial and R&D Achievements for NATESTO®
Pharmaceutical Investing Acerus Announces Expansion of NATESTO® Agreement with medac and the Submission of NATESTO® Dossier in Europe
